Skip to content

Magnera MAGN Deferred Tax Assets Capitalization Research And Development Expenditures

Deferred Tax Assets Capitalization Research And Development Expenditures at other companies

Sharplink, Inc.
 logo
Sharplink, Inc. SBET
$158K
Minerals Technologies logo
Minerals TechnologiesMTX
$12.6M+14.5%
Kopin logo
KopinKOPN
$1.45M-49.4%
Corvex
 logo
Corvex MOVE
$5.16M-27.5%
Nuvation Bio logo
Nuvation BioNUVB
$78.79M-19.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$3.03M-45.9%

Other financials

Income statement

See full
Revenue$796.0M-3.4%
Gross profit$95.0M+8.0%
Operating income$17.0M+325%
Net income-$18.0M+56.1%
EPS (diluted)-$0.50+56.5%

Balance sheet

See full
Cash & equivalents$303.0M+7.4%
Total debt$2.0B-5.4%
Total equity$1.0B-4.9%
Total assets$3.9B-4.1%

Cash flow

See full
Operating cash flow$87.0M+33.8%
CapEx$14.0M-39.1%
Free cash flow$73.0M+73.8%

Valuation

See full
Market cap$442.15M-0.2%
Enterprise value$2.1B-6.0%
P/S0.1×0.0×

Profitability

See full
Gross margin11.3%+0.5pp
Operating margin1.7%+1.6pp
Net margin-3.4%-0.5pp
FCF margin3.9%-3.2pp

Returns & leverage

See full
Return on equity-10.3%+68.5pp
Debt / equity1.9×0.0×
Current ratio2.3×-0.1×

Where this comes from

Reported directly by Magnera in its filing.

Tagged under the XBRL concept magn:DeferredTaxAssetsCapitalizationResearchAndDevelopmentExpenditures.

The official record: Magnera’s 10-K, filed November 25, 2025, on SEC EDGAR. View the filing →

Ask your AI about Magnera's deferred tax assets capitalization research and development expenditures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Magnera's deferred tax assets capitalization research and development expenditures?
Magnera (MAGN) reported deferred tax assets capitalization research and development expenditures of $10M in Q3 2025.
What does deferred tax assets capitalization research and development expenditures mean?
Represents the deferred tax asset created by the capitalization and subsequent amortization of research and development expenditures for tax purposes. This metric captures the tax benefit associated with long-term investments in innovation that are treated differently for tax reporting than for financial accounting. It serves as an indicator of the company's R&D investment intensity and its associated tax shield.